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Abstract
Objectives: To review and describe studies of the non-psychotomimetic constituent of Cannabis 
sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action. 
Method: The articles selected for the review were identified through searches in English, 
Portuguese, and Spanish in the electronic databases ISI Web of Knowledge, SciELO, PubMed, and 
PsycINFO, combining the search terms “cannabidiol and anxiolytic”, “cannabidiol and anxiolytic-
like”, and “cannabidiol and anxiety”. The reference lists of the publications included, review 
articles, and book chapters were handsearched for additional references. Experimental animal 
and human studies were included, with no time restraints. Results: Studies using animal models 
of anxiety and involving healthy volunteers clearly suggest an anxiolytic-like effect of CBD. 
Moreover, CBD was shown to reduce anxiety in patients with social anxiety disorder. Conclusion: 
Future clinical trials involving patients with different anxiety disorders are warranted, especially 
of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress 
disorders. The adequate therapeutic window of CBD and the precise mechanisms involved in its 
anxiolytic action remain to be determined.
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Introduction
Cannabis sativa is the most used drug of abuse worldwide 
and around 20% of youth use it heavily and regularly around 
the globe.1 The main psychoactive component of the plant 
is Δ9-tetrahydrocannabinol (Δ9-THC), one of the substances 
responsible for the psychoactive effects of Cannabis.2-4
Cannabidiol (CBD) is another abundant compound in 
Cannabis sativa, constituting around 40% of the plant’s active 
substances.5 The pharmacological effects of CBD are different 
and often opposite to those of Δ9-THC.6 The number of pub-
lications on CBD has increased remarkably over the last years 
and support the view that CBD has a vast array of possible 
therapeutic effects. Among these possibilities, the anxiolytic 
and antipsychotic properties of CBD stand out.7-10 CBD’s anx-
iolytic effects are apparently similar to those of approved 
drugs to treat anxiety,11 although its effective doses have not 
been clearly established and the mechanisms underlying these 
effects are not fully understood. The low affinity of CBD for 
cannabinoid neuroreceptors12,13 and its agonist properties at 
5-HT1A receptors14,15 have been repeatedly demonstrated.
Most studies on CBD have been conducted with rodents, 
but studies with human samples have also provided promis-
ing results.16,17 Therefore, the aim of this paper is to review 
the scientific literature on the anxiolytic properties of CBD 
in animal and in humans.
Method
The articles selected for this review were identified by 
searches in English, Portuguese, and Spanish in the elec-
tronic databases ISI Web of Knowledge, SciELO, PubMed, and 
PsycINFO combining the search terms “cannabidiol and anx-
iolytic”, “cannabidiol and anxiolytic-like”, and “cannabidiol 
and anxiety”. In addition, the reference lists of the selected 
articles and relevant literature reviews and book chapters 
were handsearched for additional references. We included 
experimental studies with human and animal samples with 
no time limits. We sought to exclude studies that used 
smoked Cannabis, as it is not possible to establish the dose, 
composition, and proportion of the different cannabinoids 
in this case, besides the great individual variations in the 
samples enrolled. Finally, we did not include studies using 
extracts containing both THC and CBD in oral (Cannador®) 
or oromucosal spray (Sativex®) forms due to the difficulty 
to establish the effects of CBD alone (Table 1).
Animal studies
The two first articles about the effects of CBD on experi-
mental anxiety were published in journals that were not 
indexed in the databases used for this review but were lo-
cated through handsearch in the reference lists of relevant 
literature. These two investigations showed contradictory 
results. In one study, no significant effects of high doses 
of CBD (100 mg/kg) were seen in rats in the Geller-Seifter 
conflict test.18 In the other, a low dose of CBD (10 mg/kg) 
had anxiolytic effects in rats submitted to the conditioned 
emotional response test.19
Later studies using the elevated plus maze (EPM) helped 
to elucidate this contradiction.9 The EPM consists of two 
opposing open arms (50 x 10 cm) and two closed arms 
(50 x 10 x 40 cm) that intersect in their central portion. The 
arms are made of wood and stand 50 cm above the ground. 
In this study, mice injected with CBD, diazepam or vehicle 
(no active substances) were placed in the center of the maze 
facing the closed arms. The time spent and the numbers of 
entries in the open and closed arms were measured for 10 
minutes. The frequency of entries in the open arms of ani-
mals receiving CBD presented an inverted U-shaped curve, 
with significantly higher rates than those observed in animals 
treated with vehicle, at the doses of 2.5, 5, and 10 mg/kg. 
The measures of mice treated with CBD 20 mg/kg did not dif-
fer from those of controls, suggesting that anxiolytic effects 
are only present at low doses, which explains the absence 
of effects with CBD 100 mg/kg reported in 1981.18 The same 
inverted U-shaped dose-response curve was obtained with 
a wider range of doses of CBD in the EPM (Onaivi et al.).20 
Furthermore, the same pattern was observed with the direct 
infusion of CBD in the periaqueductal gray (PAG) of rats tested 
in the EPM,15,21 confirming that anxiolytic effects should only 
be expected with low doses of CBD.
The mechanisms through which CBD acts to diminish 
anxiety have been studied in a number of animal models 
of anxiety using rodents. One of these studies used Vogel’s 
conflict test,22 in which the animal is water-deprived from 
and placed in a cage with an electrified grid at the bottom 
through which the animal receives a shock after licking wa-
ter for a predetermined number of times. Three substances 
were tested in rats using the following procedure: CBD (2.5, 
5 and 10 mg/kg), diazepam, and flumazenil (an antagonist of 
benzodiazepine receptors), in addition to vehicle (placebo). 
The tests showed that CBD produced effects consistent with 
those of diazepam by increasing the number of licks, even 
if they resulted in punishment. Flumazenil antagonized the 
anxiolytic effect of diazepam, but not that of CBD, suggesting 
that the effects of CBD are not mediated by the activation 
of benzodiazepine receptors.
There is strong evidence showing that the serotonergic 
system is involved in the anxiolytic action of CBD. The injec-
tion of the 5-HT1A receptor antagonist WAY-100635 (WAY) 
directly into the dorsolateral portion of the PAG (dlPAG) in 
rats antagonized the anxiolytic effects of CBD in the EPM and 
in Vogel’s conflict test.15 The participation of 5-HT1A recep-
tors in the anxiolytic action of CBD was also derived from 
behavioral and cardiovascular responses to restraint stress in 
rats.11 In this study, animals were intraperitoneally injected 
with vehicle or CBD (1, 10 and 20 mg/kg) and, after 30 min-
utes, they were restrained for 60 minutes. Immobilization 
increased blood pressure, heart rate, and anxiety responses 
in the EPM 24 hours later, and these effects were attenuated 
by CBD. Pretreatment with WAY blocked the anxiolytic action 
of CBD. The injection of CBD into the intra-dorsal PAG also 
blocked panic-like responses in the elevated T-maze (ETM) 
and flight responses to the electrical stimulation of this 
area.23 The ETM has three arms with the same dimensions, 
two open and one closed, and allows the measure of entrance 
avoidance in the open arms when the animal is placed in the 
closed arm, as well as of escape when the animal is placed in 
the open arm. The panic-like response seen with CBD in the 
two procedures was antagonized by the previous intra-dlPAG 
administration of WAY.22 Chronic oral administration of CBD 
also had anti-panic effects in the ETM that were neutralized 
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Table 1 Studies of the anxiolytic effect of cannabidiol in humans and animals
Study Model Route Dose Anxiolytic effect
Animals
Silveira Filho et al.18 Conflict test Intraperitoneal 100 mg/kg –
Zuardi et al.19 Conditioned emotional response 
paradigm
Intraperitoneal 10 mg/kg
+
Onaivi et al.20 Elevated plus maze test Intraperitoneal 0.01, 0.1, 0.5, 1.0, 2.5, 5.0, 
10.0, 50.0 and 100.0 mg/kg
+
Guimarães et al.9 Elevated plus maze test Intraperitoneal 2.5, 5.0, 10.0 and 20.0 mg/kg +
Moreira et al.22 Vogel’s conflict test Intraperitoneal 2.5, 5.0 and 10.0 mg/kg +
Resstel et al.10 Contextual fear conditioning Intraperitoneal 10 mg/kg +
Campos et al.15 Elevated plus maze test and Vogel’s 
conflict test 
Intra-dorsal periaqueductal gray +
Bitencourt et al.28 Contextual fear conditioning i.c.v. 2.0 microg/microl +
Campos et al.21 Elevated plus maze test Intra-dorsal periaqueductal gray 30 or 60 nmol +
Resstel et al.19 Restraint stress Intraperitoneal 1, 10 and 20 mg/kg +
Soares et al.23 Elevated T maze Intra-dorsal periaqueductal gray 15, 30 or 60 nmol +
Lemos et al.29 Contextual fear conditioning Intraperitoneal and direct 
microinjection into the PL 
prefrontal cortex 
10 mg/kg (i.p.) and 30 nmol 
(microinjection into the PL 
prefrontal cortex)
+
Casarotto et al.26 Marble-burying test Intraperitoneal 15, 30 and 60 mg/kg +
Gomes et al.30 Vogel’s conflict test Intra bed nucleus of the stria 
terminalis
15, 30, and 60 nmol +
Deiana et al.27 Marble-burying test Intraperitoneal and oral 120 mg/kg +
Uribe-Mariño et al.31 Prey-predator paradigm Intraperitoneal 0.3, 3.0 and 30 mg/kg +
Campos et al.24 Elevated T maze Oral +
Humans
Zuardi et al.7 Decreased STAI scores elevation 
induced by THC (healthy volunteers)
Oral 1 mg/kg +
Zuardi et al.32 Decreased VAS factor anxiety scores 
after public speaking  
(healthy volunteers)
Oral 300 mg +
Crippa et al.34 Decreased VAS factor anxiety scores 
before SPECT procedure  
(healthy volunteers)
Oral 400 mg +
Fusar-Poli et al.35 Decreased skin conductance 
fluctuation in task with fearful 
faces during a fMRI procedure  
(healthy volunteers)
Oral 600 mg +
Crippa et al.17 Decreased VAS factor anxiety scores 
before SPECT procedure  
(social phobia patients)
Oral 400 mg +
Bergamaschi et al.33 Decreased VAS factor anxiety scores 
after public speaking  
(social phobia patients)
Oral 600 mg +
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by intra-dlPAG injection of WAY. However, chronic administra-
tion of CBD did not change the extracellular concentration of 
serotonin in the dlPAG or the expression of 5-HT1A or 5-HT2C, 
indicating that CBD directly activates 5-HT1A receptors.24 
CBD was also found to activate the vanilloid receptor type 
1 (TRPV1)25 and there is evidence that this activation could 
explain the inverted U-shaped dose-response curve of CBD’s 
anxiolytic effect seen in the EPM. TRPV1 receptors regulate 
the release of glutamate in the dlPAG and the increased 
activation of this system would result in increased anxiety. 
Thus, it has been suggested that elevated doses of CBD in 
the dlPAG could activate local TRPV1 receptors facilitating 
the glutamatergic neurotransmission and increasing anxiety.
To test this hypothesis, rats pre-treated with the TRPV1 
antagonist capsazepine in the dlPAG were injected with CBD 
(30 and 60 mg/kg) in the same region and tested in the EPM. 
The dose of 60 mg/kg CBD, which had no anxiolytic action 
before, was able to reduce anxiety after pre-treatment 
with capsazepine, suggesting that the activation of TRPV1 
receptors by the higher dose of CBD would counterbalance 
the anxiolytic effect of CBD produced by the activation of 
5-HT1A receptors.21
Because serotonin has also been implicated in obsessive-
compulsive disorder (OCD), the effects of CBD were tested in 
mice submitted to the marble-burying test (MBT), an animal 
model of compulsive behavior. CBD induced a significant re-
duction in the number of buried marbles at different doses 
(15, 30, and 60 mg/kg) compared to controls in a dose-depen-
dent pattern. The same was found with the administration of 
the ISRS paroxetine (10 mg/kg) and diazepam (2.5 mg/kg). 
However, the effects of CBD 30 mg/kg persisted even after 
seven days of repeated daily administration, whereas the 
effects of diazepam disappeared. Pre-treatment with WAY 
(3 mg/kg) counteracted the effects of paroxetine, but did 
not affect the action of CBD, which was prevented by pre-
treatment with the CB1 receptor antagonist AM251 (1 mg/
kg).26 This action of CBD in the MBT was recently replicated 
by another group using a higher dose (120 mg/kg).27
The participation of specific cannabinoid receptors (CB1) 
in the anxiolytic action of CBD has also been investigated 
using animal models. In the study with the EPM that reported 
the antagonism of the anxiolytic effect of intra-dlPAG CBD 
by WAY, the CB1 receptor antagonist AM251 was unable to 
avoid this effect.15 However, this receptor system seems 
to be involved in another anxiolytic-like action of CBD, ac-
cording to tests using a procedure known as contextual fear 
conditioning. In this procedure, animals are pre-conditioned 
to a hostile environment (foot shocks) and later exposed to 
the same environment, when they normally present freez-
ing, the duration of which can be monitored as a measure of 
anxiety. Both CBD and diazepam are successful in attenuating 
freezing in rats, as well as the increased heart rate and blood 
pressure induced by re-exposure to the contextually feared 
environment.10 This effect of CBD on contextual memory is 
also produced by the endocannabinoid reuptake inhibitor 
AM404, which increases the availability of cannabinoids in the 
synaptic cleft.28 In this study, the two drugs were injected into 
the ventricles and their effects were counteracted by the CB1 
receptor antagonist SR141716A, suggesting the involvement 
of the endocannabinoid system in the anxiolytic action of CBD 
in this model. The pre-limbic region of the prefrontal cortex 
appears to underlie this effect of CBD, as the reduction in 
contextual fear produced by systemic administration of CBD 
(10 mg/kg) is associated with reduced c-Fos expression in 
this area. In addition, the microinjection of CBD (30 nmol) in 
the pre-limbic region of the frontal cortex reduced freezing 
induced by re-exposure to the aversive context.29 The effects 
of CBD on contextual fear indicate a possible therapeutic 
action of this cannabinoid in post-traumatic stress disorder.
Another area that is apparently involved in the anxiolytic-
like effects of CBD is the bed nucleus of the stria terminalis 
(BNST). The intra-BNST injection of CBD (15, 30, and 60 nmol) 
increased the number of punished licks in Vogel’s conflict 
test and the number of open arm entries in the EPM. These 
effects were blocked in rats pre-treated with WAY.30
CBD was also effective in an ethologic model that inves-
tigates behaviors induced by innate fear, the predator-prey 
paradigm.31 This procedure was performed using a semi-trans-
parent plexiglass box in the shape of a quadrangular arena 
(154x72x64 cm) with walls covered with a light-reflecting film 
and floor in transparent plexiglass over a board of stainless 
steel divided in 20 equal rectangles. One of the corners of the 
arena has a shelter box with black walls and a complex maze 
inside. Three days prior to the experiment, the mice were 
placed and kept in this arena, with free access to food and 
water until the day of the trial. The “no threat” group had 
its behaviors recorded for five minutes. Animals exposed to 
the predator (snake) were divided into four groups (n = 12/11 
per group) and pre-treated with intraperitoneal injections 
of CBD (0.3, 3 and 30 mg/kg) or vehicle (control group). The 
group of animals that were not confronted with the preda-
tor presented no defensive behaviors. Animals pre-treated 
with CBD had significant reductions in explosive flight and 
defensive immobility, responses related to panic models. 
Risk assessment and defensive attention were unaltered in 
animals treated with CBD. These results suggest that CBD 
can be effective in the control of panic attacks.
Human studies
The first evidence of CBD’s anxiolytic effects in humans, 
documented with assessment scales, was published in 1982 
in a study on the interaction between CBD and THC.7 The 
study sample consisted of eight volunteers with a mean 
age of 27 years, no health problems and who had not used 
Cannabis sativa in the previous 15 days. In a double-blind 
procedure, the volunteers received CBD, THC, THC + CBD, 
diazepam, and placebo in different sequences and days. 
The results showed that the increased anxiety following the 
administration of THC was significantly attenuated with the 
simultaneous administration of CBD (THC + CBD).
Based on this preliminary evidence, researchers de-
cided to investigate a possible anxiolytic action of CBD in 
experimentally induced anxiety in healthy volunteers using 
the simulated public speaking (SPS) model.32 The procedure 
consists of asking a subject to speak in front of a video camera 
for a few minutes, while subjective anxiety is measured with 
self-rated scales and physiological correlates of anxiety are 
recorded (heart rate, blood pressure, skin conductance). CBD 
(300 mg), as well as the anxiolytic drugs diazepam (10 mg) 
and ipsapirone (5 mg), administered in a double-blind design, 
significantly attenuated SPS-induced anxiety.
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The SPS test may be regarded as a good model of anxiety 
and has apparent validity for social anxiety disorder (SAD), as 
the fear of speaking in public is considered a central feature 
in this condition. Therefore, the anxiolytic effect of CBD in 
healthy volunteers observed in this test led to the hypothesis 
that this cannabinoid could be effective to treat SAD. This 
hypothesis was recently tested in 24 patients with SAD who 
had their performance in the SPS test compared to that of a 
group of 12 healthy controls.33 The patients with SAD were 
divided into two groups of 12, one of which received CBD 600 
mg and the other placebo, in a double-blind procedure. The 
results showed that the levels of anxiety, somatic symptoms, 
and negative self-assessment were higher in patients who 
took placebo than in those of the CBD group who performed 
similarly to healthy controls in some measures.
In another study that investigated the effects of CBD on 
regional cerebral blood flow (rCBF) in healthy volunteers 
using single photon emission computed tomography (SPECT), 
SPS-induced anxiety was reduced in patients receiving CBD.34 
In that study, patients received either CBD (400 mg) or pla-
cebo, in a crossed double-blind design, in two experimental 
sessions with an interval of one week. CBD significantly re-
duced subjective anxiety as measured by rating scales, while 
brain activity was increased in the left parahippocampal gyrus 
and decreased in the left amygdala-hippocampus complex, 
including the fusiform gyrus. This pattern of SPECT results 
is compatible with an anxiolytic action.
SPECT was also used later to investigate the neural cor-
relates of CBD’s anxiolytic effects in a sample of patients 
with SAD.17 A single dose of CBD 400 mg was able to reduce 
subjective anxiety measures and SPECT showed changes in 
the same regions previously identified in healthy volunteers.
Functional magnetic resonance imaging (fMRI), which 
allows the acquisition of larger series of images with better 
temporal and spatial resolution, was used to investigate 
the neural correlates of the anxiolytic effects of CBD in 
15 healthy volunteers.35 This experiment showed that CBD 
(600 mg) attenuated fMRI responses during the recognition 
of fearful facial expressions in the amygdala and the anterior 
cingulate, and that this attenuation pattern correlated with 
skin conductance responses to the stimuli. The same group 
also reported that the anxiolytic action of CBD occurs by 
altering the subcortical prefrontal connectivity via amygdala 
and anterior cingulated.16
Conclusion
Together, the results from laboratory animals, healthy vol-
unteers, and patients with anxiety disorders support the 
proposition of CBD as a new drug with anxiolytic properties. 
Because it has no psychoactive effects and does not affect 
cognition; has an adequate safety profile, good tolerability, 
positive results in trials with humans, and a broad spectrum 
of pharmacological actions,36 CBD appears to be the can-
nabinoid compound that is closer to have its preliminary 
findings in anxiety translated into clinical practice.37 Future 
studies should test this possibility in clinical trials involving 
patients with different anxiety disorders, especially panic 
disorder, obsessive-compulsive disorder, social anxiety disor-
der, and post-traumatic stress disorder. In addition, because 
the actions of CBD are biphasic, the adequate therapeutic 
window for each anxiety disorder remains to be determined. 
Regarding the mechanism underlying the anxiolytic effects of 
CBD, the most consistent evidence points to the involvement 
of the serotonergic system, probably through direct action 
on 5-HT1A receptors, although other systems, as the endo-
cannabinoid system itself, may also be implicated. Further 
investigation is warranted to clarify these issues, especially 
if we consider that CBD is a drug with a variety of effects in 
the nervous system.38-40
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